Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Accured Expenses (2016 - 2025)

OptimizeRx's Change in Accured Expenses history spans 16 years, with the latest figure at -$2.2 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 933.33% year-over-year to -$2.2 million; the TTM value through Sep 2025 reached $5.0 million, up 512.55%, while the annual FY2024 figure was $1.1 million, 19.19% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$2.2 million at OptimizeRx, down from $3.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.3 million in Q2 2025 and bottomed at -$2.2 million in Q3 2025.
  • The 5-year median for Change in Accured Expenses is $267000.0 (2024), against an average of $234216.3.
  • The largest annual shift saw Change in Accured Expenses soared 6010.65% in 2023 before it tumbled 933.33% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $536185.0 in 2021, then soared by 74.63% to $936323.0 in 2022, then decreased by 15.2% to $794000.0 in 2023, then skyrocketed by 284.13% to $3.0 million in 2024, then plummeted by 172.95% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Change in Accured Expenses are -$2.2 million (Q3 2025), $3.3 million (Q2 2025), and $854000.0 (Q1 2025).